Beschreibung
Lansoprazole, like omeprazole, inhibits CYP2C19 and reduces clopidogrel's antiplatelet efficacy, potentially increasing cardiovascular event risk.
Mechanismus
Lansoprazole inhibits CYP2C19, reducing the formation of clopidogrel's active thiol metabolite and impairing P2Y12 receptor blockade.
Klinische Bedeutung
FDA and EMA communications note reduced platelet inhibition; pantoprazole is preferred when gastroprotection is needed.
Maßnahmen
Switch to pantoprazole if PPI is needed in clopidogrel-treated patients; if lansoprazole must be used, monitor for cardiovascular events.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.